Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) Return on Sales (2019 - 2025)

Historic Return on Sales for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to 1.53%.

  • BridgeBio Pharma's Return on Sales rose 585900.0% to 1.53% in Q3 2025 from the same period last year, while for Sep 2025 it was 2.2%, marking a year-over-year decrease of 1300.0%. This contributed to the annual value of 2.45% for FY2024, which is 677700.0% up from last year.
  • BridgeBio Pharma's Return on Sales amounted to 1.53% in Q3 2025, which was up 585900.0% from 1.66% recorded in Q2 2025.
  • Over the past 5 years, BridgeBio Pharma's Return on Sales peaked at 217.55% during Q4 2021, and registered a low of 433.5% during Q3 2022.
  • For the 5-year period, BridgeBio Pharma's Return on Sales averaged around 70.9%, with its median value being 45.46% (2024).
  • Data for BridgeBio Pharma's Return on Sales shows a peak YoY increase of 13487200bps (in 2021) and a maximum YoY decrease of -4088600bps (in 2021) over the last 5 years.
  • BridgeBio Pharma's Return on Sales (Quarter) stood at 217.55% in 2021, then crashed by -136bps to 77.61% in 2022, then crashed by -42bps to 110.09% in 2023, then surged by 59bps to 45.46% in 2024, then soared by 97bps to 1.53% in 2025.
  • Its Return on Sales was 1.53% in Q3 2025, compared to 1.66% in Q2 2025 and 1.21% in Q1 2025.